Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06701656 · ClinicalTrials.gov registry record · Phase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
A Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, sponsored by PPD Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06701656: Recruiting Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, sponsored by PPD Development.
NCT06701656 is a Phase 2 study of Acute Respiratory Distress Syndrome and ARDS that is actively recruiting participants, run by PPD Development. The registered enrollment target is 200 participants, below the 361-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06701656, a Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, is actively recruiting participants, sponsored by PPD Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort C: Participants will be randomized to receive either a placebo or bevacizumab. This record describes the default procedures and analyses for Cohort C. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.
Conditions Studied
Interventions
- DRUG Cohort C: bevacizumab
- DRUG Cohort C: placebo
Study Locations (20)
California
- Community Regional Medical Center - Fresno
- Long Beach Memorial Medical Center - Long Beach
- University of California Irvine Medical Center - Orange
- University of California Davis Medical Center - Pulmonary Medicine - Sacramento
Florida
- Nova Clinical Research - Bradenton
- North Florida / South Georgia Veterans Health System - Gainesville
- Sarasota Memorial Hospital - Sarasota
Massachusetts
- Tufts Medical Center - Boston
- Lahey Hospital and Medical Center - Burlington
Michigan
- University of Michigan Hospital - Ann Arbor
- Henry Ford Health Hospital - Detroit
Alabama
- University of Alabama Hospital - Birmingham
Colorado
- Denver Health Hospital and Authority - Denver
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Idaho
- St. Luke's Boise Medical Center - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What NCT06701656 shows while recruiting
NCT06701656 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 361-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (45% lower).
The record links to 4 conditions, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Cohort C: bevacizumab is the first listed.
NCT06701656 names 20 study sites across 13 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06701656 about?
NCT06701656 is a clinical study titled "JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab". This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort C: Participants wil...
What is the current status of trial NCT06701656?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-10-28. Estimated completion is 2028-09.
What conditions does trial NCT06701656 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome, ARDS, Acute Respiratory Distress Syndrome (ARDS), ARDS (Acute Respiratory Distress Syndrome).
What interventions are being tested in trial NCT06701656?
The interventions under investigation include: Cohort C: bevacizumab (DRUG), Cohort C: placebo (DRUG).
Who is sponsoring clinical trial NCT06701656?
This trial is sponsored by PPD Development, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06701656 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06701656's enrollment target sits among peer trials
200 10th of 31 higher than 20 of 31 other Acute Respiratory Distress Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Respiratory Distress Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI